IL10 and neoplasm: However, nivolumab did not decrease IL-10 production by T cells under complete nutrient conditions, highlighting that nivolumab was more effective at promoting an anti-tumour T cell phenotype under ‘stressful’ glucose deprived and hypoxic conditions which are more reflective of the TME than full nutrient conditions.